- Home
- ORIC vs OMER Comparison
ORIC vs OMER Comparison
Compare ORIC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- OMER
- Stock Information
- Founded
- ORIC 2014
- OMER 1994
- Country
- ORIC United States
- OMER United States
- Employees
- ORIC N/A
- OMER N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- OMER Health Care
- Exchange
- ORIC Nasdaq
- OMER Nasdaq
- Market Cap
- ORIC 633.7M
- OMER 579.5M
- IPO Year
- ORIC 2020
- OMER 2009
- Fundamental
- Price
- ORIC $9.58
- OMER $9.33
- Analyst Decision
- ORIC Strong Buy
- OMER Buy
- Analyst Count
- ORIC 9
- OMER 4
- Target Price
- ORIC $18.75
- OMER $22.50
- AVG Volume (30 Days)
- ORIC 597.6K
- OMER 1.1M
- Earning Date
- ORIC 03-10-2025
- OMER 11-13-2024
- Dividend Yield
- ORIC N/A
- OMER N/A
- EPS Growth
- ORIC N/A
- OMER N/A
- EPS
- ORIC N/A
- OMER N/A
- Revenue
- ORIC N/A
- OMER N/A
- Revenue This Year
- ORIC N/A
- OMER N/A
- Revenue Next Year
- ORIC N/A
- OMER N/A
- P/E Ratio
- ORIC N/A
- OMER N/A
- Revenue Growth
- ORIC N/A
- OMER N/A
- 52 Week Low
- ORIC $6.33
- OMER $2.61
- 52 Week High
- ORIC $16.65
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- ORIC 54.79
- OMER 49.55
- Support Level
- ORIC $7.86
- OMER $8.21
- Resistance Level
- ORIC $11.15
- OMER $11.26
- Average True Range (ATR)
- ORIC 0.72
- OMER 0.93
- MACD
- ORIC 0.23
- OMER -0.20
- Stochastic Oscillator
- ORIC 52.28
- OMER 31.37
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.